Video

Dr. Kebriaei on Eligibility for Stem Cell Transplant in ALL

Partow Kebriaei, MD, discusses the eligibility criteria necessary for patients with acute lymphocytic leukemia to undergo stem cell transplantation.

Partow Kebriaei, MD, stem cell transplant physician, The University of Texas MD Anderson Cancer Center, discusses the eligibility criteria necessary for patients with acute lymphocytic leukemia to undergo stem cell transplantation.

Patients with ALL must be minimal residual disease (MRD) negative in order to qualify for transplant, Kebriaei explains. As a patient goes beyond first remission, the likelihood of achieving MRD negativity decreases. Generally, if a patient is in remission and morphologic is adequate, then they are fit to undergo transplant, says Kebriaei.

Now, patients are being taken in for transplant after their third, fourth, or fifth line of therapy. In the past, they would not be expected to obtain response; however, now these patients are obtaining response and, therefore, can receive a transplant, concludes Kebriaei.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center